Next Article in Journal
Acquired Hemophilia A Developing Cerebral Infarction 36 Days after the Frequent Administration of Bypass Hemostatic Agents
Previous Article in Journal
Long-Term Complete Remission of Early Hematological Relapse after Discontinuation of Immunosuppressants Following Allogeneic Transplantation for Sezary Syndrome
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 10
Issue 3
10.4081/hr.2018.7679
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

The Progression of Severe Aplastic Anemia to Hypoplastic Leukemia in a Long-Term Observation after the Administration of Pegylated rHuMGDF

by
Maho Ishikawa
*,
Akira Matsuda
,
Daisuke Okamura
,
Tomoya Maeda
,
Nobutaka Kawai
,
Norio Asou
and
Masami Bessho
Department of Hemato-Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka 350-1298, Saitama, Japan
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2018, 10(3), 7679; https://doi.org/10.4081/hr.2018.7679
Submission received: 13 March 2018 / Revised: 14 June 2018 / Accepted: 24 June 2018 / Published: 5 September 2018

Abstract

Thrombopoietin (TPO) is a critical regulator of hematopoiesis. We previously reported that a severe aplastic anemia (SAA) who received a short-term administration of pegylated recombinant human megakaryocyte growth and development factor (rHuMGDF). A trilineage hematologic response was induced, however the patient was diagnosed with leukemia after nine years and eight months from administration of rHuMGDF. In recent reports, somatic mutations in myeloid cancer candidate genes were present in one-third of the AA. A mutant clone may be expanded by rHuMGDF in our patient. The long-term safety of patients treated with TPO and eltrombopag remains unknown. Careful observations are warranted hereafter.
Keywords: aplastic anemia; acute myeloid leukemia; thrombopoietin; clonal evolution aplastic anemia; acute myeloid leukemia; thrombopoietin; clonal evolution

Share and Cite

MDPI and ACS Style

Ishikawa, M.; Matsuda, A.; Okamura, D.; Maeda, T.; Kawai, N.; Asou, N.; Bessho, M. The Progression of Severe Aplastic Anemia to Hypoplastic Leukemia in a Long-Term Observation after the Administration of Pegylated rHuMGDF. Hematol. Rep. 2018, 10, 7679. https://doi.org/10.4081/hr.2018.7679

AMA Style

Ishikawa M, Matsuda A, Okamura D, Maeda T, Kawai N, Asou N, Bessho M. The Progression of Severe Aplastic Anemia to Hypoplastic Leukemia in a Long-Term Observation after the Administration of Pegylated rHuMGDF. Hematology Reports. 2018; 10(3):7679. https://doi.org/10.4081/hr.2018.7679

Chicago/Turabian Style

Ishikawa, Maho, Akira Matsuda, Daisuke Okamura, Tomoya Maeda, Nobutaka Kawai, Norio Asou, and Masami Bessho. 2018. "The Progression of Severe Aplastic Anemia to Hypoplastic Leukemia in a Long-Term Observation after the Administration of Pegylated rHuMGDF" Hematology Reports 10, no. 3: 7679. https://doi.org/10.4081/hr.2018.7679

Article Metrics

Back to TopTop